BioSpace News Archive

OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced its financial results for the three months ended June 30, 2022.

Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the second quarter ended June 30, 2022.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced second quarter 2022 financial results and a business update.

Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced financial results for the second quarter ended June 30, 2022 and a midyear corporate update.

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2022.

Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), today reported second quarter financial results for the period ended June 30, 2022.

BioLife Solutions, Inc., a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies and the broader biopharma markets, announced financial results for the three and six months ended June 30, 2022.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted nine new employees options to purchase a total of 22,100 shares of the Company’s common stock at an exercise price per share of $27.35, which was the closing price on August 8, 2022, and restricted stock units to acquire a total of 11,050 shares of the Company’s common stock.

Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, reported business updates and financial results for its second quarter ending June 30, 2022.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarter 2022 financial results, unveiled new positive data from the Phase 2 MARIO-275 clinical trial, and provided a business update.